Neurotransmitters as Regulators of Tumor Angiogenesis and Immunity: The Role of Catecholamines

被引:0
作者
Chandrani Sarkar
Debanjan Chakroborty
Sujit Basu
机构
[1] The Ohio State University,Department of Pathology
[2] The Ohio State University,Arthur G. James Comprehensive Cancer Center
来源
Journal of Neuroimmune Pharmacology | 2013年 / 8卷
关键词
Catecholamine; Tumor; Angiogenesis; Immunity;
D O I
暂无
中图分类号
学科分类号
摘要
The growing tumor employs various strategies to establish its growth, progression and spread in the host. Angiogenesis or formation of new blood vessels from existing ones and escape from immune surveillance are the two critical steps that ensure proper establishment and growth of the newly formed tumor. Thus understanding the novel pathways associated with tumor angiogenesis and immunity may lead to the development of newer therapeutic strategies using the regulators of these pathways to improve patient outcomes. These two pivotal steps in the process of tumorigenesis are governed by plethora of endogenous factors. The neuroendocrine molecules, which include the catecholamine neurotransmitters, dopamine, norepinephrine and epinephrine are of growing interest considering their varied and diverse regulatory roles both in the process of tumor angiogenesis and tumor immunity. This review focuses on the emerging roles of catecholamines in modulating tumor angiogenesis and immunity, and also discusses the probable molecular mechanisms of their actions. Understanding of this new group of endogenous regulators of tumor growth may lead to the development of newer therapeutic approaches for the treatment of cancer.
引用
收藏
页码:7 / 14
页数:7
相关论文
共 539 条
[1]  
Alvarez C(2007)Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction J Clin Endocrinol Metab 92 2931-2937
[2]  
Martí-Bonmatí L(2006)The influence of bio-behavioural factors on tumour biology: pathways and mechanisms Nat Rev Cancer 6 240-248
[3]  
Novella-Maestre E(2008)Reduced tumor growth in a mouse model of schizophrenia, lacking the dopamine transporter Int J Cancer 123 511-518
[4]  
Sanz R(1999)Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization Circ Res 85 221-228
[5]  
Gómez R(1971)Catecholamine functions Annu Rev Physiol 33 1-30
[6]  
Fernández-Sánchez M(2011)Evolution of beta-blockers: from anti-anginal drugs to ligand-directed signalling Trends Pharmacol Sci 32 227-234
[7]  
Simón C(2008)Harnessing serotonergic and dopaminergic pathways for lymphoma therapy: evidence and aspirations Semin Cancer Biol 18 218-225
[8]  
Pellicer A(2011)Beta blockers and breast cancer mortality: a population- based study J Clin Oncol 29 2635-2644
[9]  
Antoni MH(2007)Glucose metabolism and catecholamines Crit Care Med 35 S508-S518
[10]  
Lutgendorf SK(2000)Dopamine, a neurotransmitter, influences the immune system J Neuroimmunol 102 113-124